Search

everythinglearnresearchcommunity

for

Search:↓

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

A user's successful hair regrowth after 7 months of using 5% minoxidil, 1mg finasteride, and adding micro needling 4 months ago. The user also took biotin, fish oil, and collagen supplements, and reduced finasteride intake to once every 3 days due to minor libido decay.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A 33-year-old male with a receding hairline is advised to start with finasteride to block DHT and consider minoxidil for promoting hair growth. Other treatments like copper peptides and serums are deemed less effective, and ketoconazole shampoo is suggested for scalp health.

A 30-year-old shared their 7-month hair regrowth progress using topical minoxidil twice daily, 1 mg finasteride daily, and weekly microneedling. Users discussed the effectiveness of these treatments and suggested adding retinol for better results.

Several new hair loss treatments are in development, with Cosmo Breezula and Kintor KX826 being the furthest along, expected to be commercialized by 2027. Veradermics is the only treatment in pill form, while others like KX/GT/Breezula will be topical.

Exploring the potential of exosomes to treat hair loss and discussing the effectiveness of treatments such as Minoxidil, Finasteride and RU58841.

The user is addressing hair loss with finasteride, dutasteride, oral and topical minoxidil, dermarolling, and shampoos. They are considering adding essential oils to improve circulation.

AB-103, a minoxidil sulfotransferase stimulant, is discussed as a potential hair loss treatment. Users inquire about effective boosters for hair growth.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.